Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S253060, C514S253090, C514S254020, C514S254040, C514S254050, C514S254080, C514S323000, C514S417000, C544S238000, C544S295000, C544S363000, C544S364000, C544S366000, C544S367000, C544S370000, C544S373000, C546S200000, C546S277100, C548S455000, C548S466000, C548S472000
Reexamination Certificate
active
08008299
ABSTRACT:
This invention is directed to a compound of Formula (I):and forms thereof, wherein A, B, E, G, X and L2are as defined herein and their use as urotensin II receptor antagonists.
REFERENCES:
patent: 6583144 (2003-06-01), Ohkura et al.
patent: 6884887 (2005-04-01), Riermeier et al.
patent: 6911464 (2005-06-01), Man et al.
patent: 7043052 (2006-05-01), Rhoads
patent: 2004/0259873 (2004-12-01), Man et al.
patent: 2004/0267051 (2004-12-01), Boerner et al.
patent: 2005/0203090 (2005-09-01), Man et al.
patent: 2007/0027163 (2007-02-01), Bissantz et al.
patent: WO 98/52919 (1998-11-01), None
patent: WO 01/05741 (2001-01-01), None
patent: WO 01/05741 (2001-01-01), None
patent: WO 03/014061 (2003-02-01), None
patent: WO 2004/078114 (2004-09-01), None
patent: WO 2004/080422 (2004-09-01), None
patent: WO 2004/080422 (2004-09-01), None
patent: WO 2004/080423 (2004-09-01), None
patent: WO 2004/080423 (2004-09-01), None
patent: WO 2005/034873 (2005-04-01), None
patent: WO 2005/034873 (2005-04-01), None
patent: WO2007/081995 (2007-07-01), None
patent: WO 2008/153902 (2008-12-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
European Search Report, Application No. 08768153.2-1219/2161994; PCT/US2008007076.
International Search Report, PCT/US08/07076, Jun. 5, 2008.
Pearson et al, “Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes,” Proc. Natl. Acad. Sci. USA, 1980, pp. 5021-5024, vol. 77, No. 8.
Ames, et al, “Human-urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14,” Nature, 1999, pp. 282-286, vol. 401, London.
Tal, et al, “A Novel Putative Neuropeptide Receptor Expressed in Neural Tissue, Including Sensory Epithelia,” Biochem. Biophys. Res. Commun., 1995, pp. 752-759, vol. 209.
Marchese, et al, “Cloning and Chromosomal Mapping of Three Novel Genes, GPR9, GPR10, and GPR14, Encoding Receptors Related to Interleukin 8, Neuropeptide Y, and Somatostatin Receptors,” Genomics, 1995, pp. 335-344; vol. 29.
Conlon, et al, “Distribution and Molecular Forms of Urotensin II and its role in Cardiovascular Regulation in Vertebrates,” J. Exp. Zool., 1996, pp. 226-238, vol. 275.
Bohn, et al, “Urotensin II evokes potent vasoconstriction in humans in vivo,” Br. J. Pharmacol., 2002, pp. 25-27, vol. 135.
Douglas, et al, “Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardiovascular Disease,” Trends Cardiovasc. Med., 2000, pp. 229-237, vol. 10.
Zou, et al, “Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats,” FEBS Letters, 2001, pp. 57-60, vol. 508.
Watanabe, et al, “Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells,” Circulation, 2001, pp. 16-18, vol. 104.
Lim, et al, “Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure,” Circulation, 2004, pp. 1212-1214, vol. 109.
Bousette, et al, “Increased expression of urotensin II and its cognate receptor GPR 14 in atherosclerotic lesions of the human aorta,” Antherosclerosis, 2004, pp. 117-123, vol. 176.
Totsune, et al, “Role of urotensin II in patients on dialysis,” Lancet, 2001, pp. 810-811, vol. 358.
Totsune, et al, “Increased plasma urotensin II levels in patients with diabetes mellitus,” Clin. Sci., 2003, pp. 1-5, vol. 104.
Gartlon, et al, “Central effects of urotensin-II following ICV administration in rats,” Psychopharmacology, 2001, pp. 426-433, vol. 155.
Gartlon, et al, “Urotensin-II, a neuropeptide ligand for GPR 14, induces c-fosin the rat brain,” Eur. J. of Pharmacol., 2004, pp. 95-98, vol. 493.
Matsumoto, et al, “Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents,” Neuroscience Letters, 2004, pp. 99-102, vol. 358.
Kinney, et al, “Structure-Function Analysis of Urotensin II and its Use in the Construction of a Ligand-Receptor Working Model”, Angew. Chem. Int. Ed., 2002, pp. 2940-2944, vol. 41, No. 16.
Silvestre, et al, “Inhibition of Insulin Release by Urotensin II—A Study on the Perfused Rat Pancreas,” Horm. Metab. Res., 2001, pp. 379-381, vol. 33.
Gillaspy, et al, “A Simple Method for the Formation of Cycolpropylamines: The First Synthesis of Tricyclopropylamine,” Tetrahedron Letters, 1995, pp. 7399-7402, vol. 36.
Qi et al, “Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors,” Peptides, 2005, pp. 683-690, No. 26, Elsevier.
Ghosh Shyamali
Kinney William A.
Lawson Edward C.
Luci Diane K.
McComsey David F.
Bernhardt Emily
Janssen Pharmaceutica N.V.
Stercho Yuriy P.
LandOfFree
Urotensin II receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urotensin II receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urotensin II receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2703867